STUDresearch · Peptide
KPV
Also known as
Lys-Pro-Val · Lysine-Proline-Valine · alpha-MSH fragment KPV · α-MSH(11-13) · α-MSH 11-13 · MSH 11-13 · KPV tripeptide · alpha-MSH C-terminal tripeptide · Ac-KPV (acetylated forms discussed)
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Lots of talk
Mixed
Oral / SubQ
Gut & inflammation peptides
Mixed — oral for gut-first, SubQ for whole-body calm, topical for skin. Pick a job.
What people say
KPV is the Lys-Pro-Val tripeptide from the C-terminus of α-MSH. PepT1 transport, inflammatory signaling and oral benefit are supported mainly by cell and mouse colitis work, not human IBD trials.
Doses people talk about
These are self-reports, not instructions. Route, product identity, gut condition, concurrent BPC/KLOW/NAD use and outcome definitions varied.
How it may feel
Amount-bearing reports conflict from the first days: some describe fullness, less gas or immediate relief, while others report bloating, diarrhea, stomach pain, dizziness, headaches or no clear improvement.
Early SubQ report200 mcg SC once daily
One user described fullness and less gas by the third injection; the author explicitly remained unsure whether KPV caused the changes.
Higher SubQ report500 mcg SC twice daily for 1 week
One commenter reported immediate benefit, then added BPC-157 at the same amount, preventing clean persistence attribution.
Adverse SubQ report250 mcg SC once
A user reported severe bloating/gas and later diarrhea; a separate thread also described stomach upset after a 500 mcg first use.
Low oral report50 mcg oral once daily through day 5
A promotional-community post used a third-person euphemism for self-use and claimed gut, skin and libido changes plus marked anhedonia; product and authorship context reduce reliability.
Half-life & effect duration
- Half-life in the body
- Oral or injectedNo settled estimate
- Felt duration people report
- First week onwardGut or appetite improvement in some accounts; no response in others
- Other experiencesHeadaches, dizziness, bloating, diarrhea or stomach pain
Cycles people discuss
Community blocks range from short tests to multi-week or ongoing use, but there is no evidence-based human cycle and the same threads contain both early benefit and early intolerance.
Timing
Preserved oral-use notes describe morning use, meals, or about 20–30 minutes before food. Injectable blend schedules are a different discussion; no human evidence here establishes one best clock across routes.
Stacks
BPC-157, TB-500, GHK-Cu and KLOW frequently accompany KPV, so improvements and adverse effects in stacked reports cannot be assigned cleanly to KPV.
Access talk
Not IBD approval: Mouse colitis lore and a compounding-list vote are not a licensed Crohn’s/UC drug.
Labs people mention
Inflammation labs: hs-CRP is what generic 2026 peptide-monitoring posts name.
Watch for
Route oversell: Oral PepT1 story from inflamed-mouse colon models does not prove every capsule reaches diseased human mucosa at a useful concentration.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
No dependable human parent-compound elimination half-life was established for oral, SubQ or IV KPV in the checked material.
The formal paper studied PepT1 transport in human cell lines and oral KPV in mouse colitis; community posts supplied schedules and felt claims but no analyte concentration-time measurements.
Cell transport, mouse oral exposure, dosing frequency and felt duration cannot be converted into human systemic PK.
- PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation (opens in a new tab)Methods, results and discussion: human epithelial/T-cell transport and signaling assays plus 100 micromolar KPV in drinking water in DSS- and TNBS-induced mouse colitis.Cell and mouse evidence, not a human oral efficacy trial or human systemic pharmacokinetic study; the mouse drinking-water concentration is not a consumer dose.
- Reddit r/KPVPeptide — Day 3 on KPV (opens in a new tab)Original post: 200 mcg SC daily with fullness and less gas by day 3; comments include four-month twice-daily use, 500 mcg once daily without benefit and a claimed 500 mcg twice-daily IV routine.Anonymous, uncontrolled and internally inconsistent route/product reports; no laboratory confirmation or standardized outcomes.
- Reddit r/KPVPeptide — KPV best timing for gut (opens in a new tab)Original twice-daily SubQ discussion and comments: 500 mcg twice daily for one week with claimed immediate benefit; another user reported gut worsening at 300, 150 and 75 mcg.Anonymous products, self-selected outcomes, inconsistent co-use and unsupported claims about 30-minute systemic duration and “die-off.”
Felt duration people report
Reports conflict from the first week through longer use: early gut or appetite improvements coexist with no response, headaches, dizziness, bloating, diarrhea and stomach pain.
Amounts ranged from 50 mcg oral through 200–500 mcg SC schedules; some later claims were confounded by BPC-157, KLOW or other agents.
Anonymous self-selection, unverified products, different routes and conditions, co-interventions and subjective endpoints prevent a typical onset or persistence range.
- Reddit r/KPVPeptide — Day 3 on KPV (opens in a new tab)Original post: 200 mcg SC daily with fullness and less gas by day 3; comments include four-month twice-daily use, 500 mcg once daily without benefit and a claimed 500 mcg twice-daily IV routine.Anonymous, uncontrolled and internally inconsistent route/product reports; no laboratory confirmation or standardized outcomes.
- Reddit r/KPVPeptide — KPV best timing for gut (opens in a new tab)Original twice-daily SubQ discussion and comments: 500 mcg twice daily for one week with claimed immediate benefit; another user reported gut worsening at 300, 150 and 75 mcg.Anonymous products, self-selected outcomes, inconsistent co-use and unsupported claims about 30-minute systemic duration and “die-off.”
- Reddit r/Longcovidgutdysbiosis — KPV peptides (opens in a new tab)Comments include 400 mcg daily SubQ with later BPC/TB/GHK co-use, a 500 mcg first-use stomach reaction, and 250 mcg SubQ bloating/gas.Different users and conditions, unverified products, concurrent peptides and sparse follow-up.
- Reddit r/Longcovidgutdysbiosis — KPV peptide side effects (opens in a new tab)Comments describe dizziness after about one week and a first 250 mcg SubQ use followed by gastrointestinal symptoms amid NAD, breakfast, pre-workout and exercise.Anonymous reports with substantial same-day co-exposures, uncertain dose histories and no clinical causality assessment.
- Reddit r/NTNPerformance — KPV anhedonia side effects (opens in a new tab)Post describes oral 50 mcg use through day 5 with claimed gut, skin and libido changes plus pronounced anhedonia, using a third-person euphemism for the subject.Promotional community context, unclear authorship framing, unverified product and a single uncontrolled account.
Other context in this card
- Reddit r/KPVPeptide — Welcome to the KPV Peptide Community (opens in a new tab)Original 1 mg daily claim and comments describing 150 mcg daily, 250 mcg SubQ with bloating/gas/jitters and later stopping after severe gas pain and diarrhea.Community-founder framing, anonymous users, unverified products and no controlled assessment.
What people say
- Gut comfort (user logs): Calmer GI days, less post-meal irritation, fewer “flare-like” windows over multi-week runs. forum
- IBD / colitis interest: Threads link KPV to Crohn’s-/colitis-style stories and “leaky gut” language — anecdotes and animal models, not controlled human outcomes. forum
- vs full α-MSH / MT-II: Anti-inflammatory lore without tanning, appetite, or sexual-side melanotan culture. forum
- MCAS / histamine adjacent: Some allergy/MCAS boards experiment with KPV + BPC for “immune noise”; responses highly mixed and confounded. anecdote
- Stack halo: BPC-157 + KPV (and KLOW four-ways) make single-agent credit unreliable. forum
- Women vs men: Not a loud sex-split dose culture. Gut/inflammation charts are shared; pregnancy/breastfeeding still treated as avoid. forum
- Mouse colitis (oral / local delivery): DSS and TNBS models — reduced disease activity, histology scores, myeloperoxidase (neutrophil) activity, and colonic cytokines after KPV. animal
- PepT1 targeting story: Inflamed colon upregulates PepT1; KPV transport into epithelial/immune cells framed as preferential uptake in disease tissue (knockout work abolishes benefit in models). animal
- Nanoparticle delivery (preclinical): HA-functionalized oral nanoparticle KPV improved colitis metrics at much lower free-peptide doses in mice — not proof simple capsules match that. animal
- Colitis-associated cancer models: Oral KPV reduced tumor number/burden in mouse colitis-associated tumorigenesis work (PepT1-dependent in cited studies). animal
- NF-κB / cytokines: Lab systems show reduced NF-κB activation and pro-inflammatory cytokine readouts (TNF-α, IL-1β, IL-6 class). lab
- Skin / dermatitis models: Contact hypersensitivity and keratinocyte inflammation models show calmer inflammatory readouts; users report calmer irritated or flare-prone skin. animal
- Antimicrobial angle: α-MSH-related peptides including KPV show lab activity vs some pathogens (e.g., *S. aureus* including MRSA strains, *Candida*) — not clinical infection treatment. lab
Doses people talk about
- Subq “start low” band: ~100–200 mcg/day common first week for tolerance checks. forum
- Subq common working band: ~200–500 mcg/day once daily is the most repeated injectable chart range. forum
- Subq higher community band: ~0.5–1 mg once or twice daily appears often in 2025–2026 protocol writeups; some logs go toward ~2 mg/day total — still anecdotal. forum
- Oral common band: ~500–1,500 mcg/day (often once daily; sometimes split AM/PM) for gut-first talk. forum
- Oral higher band: ~1–2 mg/day solution or capsule is widely cited for “colitis / leaky gut” style goals; multi-mg claims above that are less consistent and poorly verified. forum
- Oral empty-stomach lore: Many gut threads prefer empty stomach ~20–30 min before food; not standardized science. forum
- Split dosing: 2× daily oral or inject for “steadier coverage” given short-peptide half-life assumptions. forum
- 5-on / 2-off charts: Some vendor calculators list weekday-on / weekend-off with ~250–500 mcg working doses — schedule is culture, not trial design. forum
- Topical: Compounded cream/gel strengths often discussed ~0.1–0.5% w/w; some anecdote protocols cite multi-mg applied amounts twice daily — strengths poorly standardized across sources. forum
- Route pick logic: Oral = gut-first / PepT1 story; subq = systemic inflammation talk; topical = local skin; do not treat mcg oral ≡ mcg inject as proven equivalent. forum
- With BPC-157 stack: Keep each agent in its own usual mcg band (e.g., KPV ~200–500 mcg + BPC ~250–500 mcg) rather than “double everything.” forum
- Separate vs pre-mix: Purists dose KPV alone (or oral KPV) on its schedule and run BPC/TB/GHK separately so TB is not forced daily with a fixed 50/10/10/10 ratio. forum
- Purity / identity caveat: Same labeled mcg may not match across gray-market capsules vs lyophilized vials; COA batch match is the community quality ask. forum
- Weird outlier charts: Occasional “250 mg twice daily oral” style numbers appear on low-quality dose pages — treated as errors or unit mistakes by careful readers, not standard practice. forum
- U-100 tiny-draw fight: A copied 10 mg + 2 mL chart makes 200 mcg ≈ 4 units on a U-100 — easy to misread. Other camps add more water so 500 mcg lands near 10 units. Units follow the water, not the peptide name. forum
- Nasal minority camp: Because it is small, nasal KPV gets sold and discussed more than nasal TB. Still a side path vs oral gut-first or SubQ systemic charts, and still no human nasal PK package. forum
- Salt-form caveat: Acetate vs TFA salt changes labeled mass vs free-base peptide slightly; mostly ignored in bro charts but noted in careful chem talk. forum
- Framing: All figures below are research-community / vendor-chart discussion — not prescriptions, not FDA dosing, not safety-validated human protocols. forum
- No human RCT dose: Published human clinical dosing for IBD/skin/systemic use is not established; ranges are extrapolated and forum-normalized. trial
How it may feel
- Days 1–3: One 200 mcg/day SC user described fullness and less gas by day 3, while other 250–500 mcg SC reports described bloating, gas, stomach upset or no clear benefit. These uncontrolled accounts conflict. forum
- First week: Reports ranged from immediate improvement at 500 mcg twice daily to gut worsening after 300, 150 or 75 mcg, dizziness, and severe bloating or diarrhea after 250 mcg. “Die-off” explanations were user speculation, not verified mechanisms. forum
- Weeks 1–2: Gut-focused users who benefit often claim fewer irritation or post-meal flare days; skin users may note subtle calm. forum
- Weeks 2–4: Common checkpoint for oral gut protocols — clearer trajectory or rethink dose, route, diet triggers, purity. forum
- Weeks 4–8: Typical full research block for inflammation/gut goals; stubborn symptoms more often prompt stack/route change than pure dose doubling. forum
- Month 2+: Long continuous logs exist but are sparse and confounded; maintenance talk is habit, not trial data. forum
- No change ~3–4 weeks: Recheck food triggers, concurrent meds/supps, capsule identity, and whether oral vs inject route matches the goal — don’t auto-double. forum
- After stop: Some keep calmer GI for a stretch; others rebound when diet stress, travel, or known triggers return. anecdote
- Quiet first days vs week 2–4: Most oral logs are not a day-1 “feel.” The gut checkpoint people use is weeks 2–4 of fewer irritation days — or nothing, then they rethink route and diet. forum
- Bloodwork people mention: hs-CRP is the generic inflammation lab. Gut-goal threads sometimes add fecal calprotectin. There is no established “KPV level.” forum
Around the dose
- Clock: Oral gut talk is often morning or around meals. Injectable follows the KLOW morning pin. forum
- Training: Not a performance peptide. People don’t usually pre-load KPV for a PR. forum
- Route = job: Oral for gut-first; SubQ for systemic calm talk; topical for skin. Picking one job is the habit. forum
- Gut habits: Sleep, not stacking NSAIDs, and not chasing a new food every week get mentioned more than extra mcg. forum
- vs KLOW: Unbundle to oral KPV when the gut is the job and you don’t want lockstep GHK. forum
- Empty-stomach oral lore: Many gut threads dose ~20–30 min before food. Not a trial lock. forum
Cycles people discuss
- Common research block: ~4–8 weeks on for gut/inflammation goals. forum
- Extended blocks: ~8–12 weeks appear in longer inflammation and KLOW-style guides. forum
- Short test: ~2–4 weeks for oral tolerance, first flare window, or “is this doing anything” check. forum
- Vendor-style on/off: Some charts show ~8 weeks on / ~8 weeks off or multi-week breaks after a block. forum
- 5-on / 2-off: Weekday dosing with weekend breaks shows up in injectable calculators — optional culture, not proven necessity. forum
- Continuous vs pulse: Daily through stubborn GI seasons, or pulsed around known triggers (travel, diet slips, flare seasons). forum
- Time off: No shared evidence-based schedule — stop when goals met, sides appear, or budget/logistics force a break. forum
- Re-runs: Common on later flares; long-term human safety database does not exist. forum
Timing
- Systemic half-life not established: Being an unmodified tripeptide does not supply a human parent-compound half-life; the checked human self-reports did not measure exposure, and mouse oral PepT1 work is not SubQ PK. forumanimal
- Why daily / BID: Short perceived duration drives once- or twice-daily use rather than weekly (contrast TB-500 culture). forum
- Oral vs subq PK: Oral framed as local gut epithelial exposure via PepT1; subq as brief systemic pulse — not dose-equivalent routes. forum
- Downstream feel: Some users say gut calm outlasts any plausible plasma presence (tissue/signaling lag lore). anecdote
- Oral timing practices: Empty stomach or away from large protein meals is common advice; practices vary and are not trial-locked. forum
- Injection timing: Morning consistency preferred in many logs; no controlled AM vs PM comparison. forum
- Human PK gap: No solid published human pharmacokinetic package for research KPV dosing culture. trial
- Nanoparticle vs free oral: Mouse nanoparticle colon delivery data should not be assumed for plain water/capsule oral product. animal
More on what it is
- Why people care: Gut/inflammation forums treat it as the “anti-inflammatory bit” of α-MSH without the melanotan-style tanning drive. forum
- Receptor debate: Some writeups say KPV retains anti-inflammatory action with little classical melanocortin receptor binding/pigment signaling; others still mention MC1R/MC3R context for the parent pathway — forums blur these. forum
- 2026 compounding-vote headline: July 23, 2026 FDA PCAC voted 8–6 (1 abstention) to recommend KPV free base and acetate for the 503A bulks list. Reviewed for wound healing and inflammatory conditions — not as an approved IBD drug. trialforum
- Not FDA-approved: Advisory compounding recommendation only. Same “not a final 503A listing / not a drug approval” confusion as BPC and TB-500. trialforum
- Nasal size honesty: At ~342 Da, KPV sits well under the ~1,000 Da community “nasal might work” cutoff — unlike BPC (~1,400 Da) or full-length Tβ4-weight tables. That is physics talk, not published human nasal PK. Oral gut and SubQ still dominate logs. forumtrial
- What it is: Naturally occurring tripeptide Lys-Pro-Val; C-terminal fragment α-MSH positions 11–13; research peptide only — not an approved IBD, skin, or infection drug. trial
- Size / ID talk: Small ~339–342 Da free-acid class peptide (salt form MW shifts with acetate/TFA); CAS often listed ~67727-97-3 in vendor chem sheets. trial
- Mechanism talk (preclinical): NF-κB pathway dampening and lower TNF-α / IL-1β / IL-6–class cytokines; gut uptake via PepT1 (SLC15A1) is the headline oral story. animal
- Evidence honesty: Mouse colitis and cell work are denser than large human RCTs for IBD, systemic inflammation, or consumer skin use. trial
- Not this: Not full α-MSH, not Melanotan I/II, not afamelanotide, not a steroid, not an FDA-approved gut or dermatology drug. trial
Stacks
- Gut dual (most common): KPV + BPC-157 — top “gut repair + inflammation calm” pair; complementary lore (repair/angiogenesis talk vs NF-κB calm). forum
- Repair trio: KPV + BPC-157 + TB-500 for gut + soft-tissue recovery threads. forum
- KLOW four-way: GHK-Cu + BPC-157 + TB-500 + KPV (GLOW + KPV); often sold ~50/10/10/10 mg in 80 mg vials — ratios vary. forum
- GLOW contrast: GLOW = GHK-Cu + BPC + TB without KPV; adding KPV is the “inflammation/gut” marketing step-up. forum
- Skin pair: KPV + GHK-Cu in barrier, redness, post-procedure calm threads. forum
- Barrier / antimicrobial speculation: Occasional KPV + LL-37 — high speculation, immune/infection caution. forum
- Immune-mod talk: KPV + Thymosin Alpha-1 appears in broader immune/inflammation boards. forum
- MCAS-adjacent experiments: KPV ± BPC ± TA-1 on sensitive-immune forums — confounded, low evidence. anecdote
- Lifestyle co-credit: Elimination diet, sleep, stress, and probiotic changes often co-occur with “wins.” forum
- Avoid mega-stacking: Experienced threads warn against piling KPV into already-crowded multi-injectable protocols without a reason each agent is there. forum
Access talk
- Not IBD approval: Mouse colitis lore and a compounding-list vote are not a licensed Crohn’s/UC drug. trialforum
- Not a final rule: Advisory only; same unfinished rulemaking story as BPC and TB-500. trialforum
- April 2026 Category 2 off: Not the same as Category 1, 503A placement, or FDA approval. trialforum
- Capsules vs vials vs future 503A: Oral RUO, injectable research vials, and a possible later compounded product get sold as one nickname. forum
- July 23, 2026 PCAC: 8–6, one abstention, for KPV free base and acetate on the 503A bulks list. Reviewed for wound healing and inflammatory conditions. trial
Labs people mention
- Inflammation labs: hs-CRP is what generic 2026 peptide-monitoring posts name. forum
- Gut-specific talk: Fecal calprotectin shows up when the job is IBD-style or “is my gut actually quieter.” Not a standard start-here panel. forum
- No KPV blood level: People judge stool days and skin calm, not a peptide concentration. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
- Tiny ticks: People argue 2 vs 4 vs 10 units for the same mcg because vial size and BAC volume differ. A 4-unit draw on a U-100 is a known beginner miss. forum
Watch for
- Injection site: Mild short-lived redness, itch, or tenderness — common peptide subq complaint. forum
- Oral GI: Occasional loose stool, nausea, cramping, or appetite shift in first 1–2 weeks. forum
- Headache / fatigue: Mild headache, brief lethargy, or “muted” feel reported by a minority — especially multi-peptide stacks. forum
- Flu-like pulse: Transient flu-like symptoms after subq noted in clinic-facing writeups for injectables generally. forum
- Topical local: Sting, redness, or dryness from cream/gel base or concentration. forum
- “Herx” claims: Some users attribute early symptom flares to antimicrobial/immune modulation — contested; not a validated mechanism for consumer dosing. anecdote
- Insomnia in stacks: Occasional sleep disruption reported when KPV is combined with BPC or other agents — attribution unclear. anecdote
- Not a steroid substitute: Mouse “no notable sides” language is not a human safety package; infection risk, autoimmunity shifts, and drug interactions are poorly mapped. forum
- Source / gray-market risk: Mislabel, under/over-dose, capsule identity uncertainty, endotoxin/sterility unknowns on non-pharmacy research vials. forum
- Route oversell: Oral PepT1 story from inflamed-mouse colon models does not prove every capsule reaches diseased human mucosa at a useful concentration. forum
- Blend ratio trap: Fixed KLOW 50/10/10/10 can overshoot GHK goals or force daily TB contrary to classic TB weekly charts. forum
- Sports / status caution: Unapproved peptides often fall under broad anti-doping “non-approved substance” logic even when not named line-by-line — athletes should assume risk. forum
- Safety frame: No MT-II tan story ≠ proven long-term safety; stop and reassess if severe allergy, worsening GI bleed-type symptoms, or systemic illness appears — research context only. forum
- “FDA approved KPV” mix-up: PCAC-yes for wound/inflammation compounding talk is not an IBD approval and not a purity stamp on RUO capsules. forumtrial
- Evidence gap: No large human RCTs establishing efficacy or long-term safety for IBD, systemic inflammation, or consumer dermatology. trial
- Regulatory posture: Research-only / not FDA-approved therapeutic; compounding and bulk-substance category chatter changes over time and is jurisdiction-specific. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.